Antibody Therapeutics Market by Format, Route of Administration, Source, Disease Areas, End User

Description

List of Tables

[188 Pages Report] The Antibody Therapeutics Market size was estimated at USD 248.79 billion in 2023 and expected to reach USD 285.77 billion in 2024, at a CAGR 14.89% to reach USD 657.50 billion by 2030.

Global Antibody Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023]	USD 248.79 billion
Estimated Year [2024]	USD 285.77 billion
Forecast Year [2030]	USD 657.50 billion
CAGR (%)	14.89%

Antibody therapeutics are a class of medical treatments that employ antibodies to mimic or enhance the immune system's ability to fight diseases. The precision of antibody therapeutics allows for tailored treatments that provide high specificity and lower toxicity profiles than conventional drugs, making them effective in treating various conditions, including cancers, autoimmune diseases, and infectious diseases. The increasing incidences of chronic diseases and increased healthcare expenditure globally have increased the adoption of antibody therapeutics. However, high costs associated with development and lengthy and complex regulatory approvals limit the penetration of antibody therapeutics. Nevertheless, advancements in medical technology are leading to more productive antibody production. In addition, the emergence of next-generation antibodies and supportive government initiatives for cancer care and treatments are expected to offer potential opportunities for the antibody therapeutics market.

Regional Insights

In the Americas, antibody therapeutics market exhibit robust growth supported by a well-established R&D ecosystem, extensive patent portfolio, and high healthcare expenditure. Furthermore, the Americas includes numerous biopharmaceutical giants, which dedicate substantial resources to developing monoclonal antibodies and novel drug discovery. The Asia-Pacific region experienced a surge in the need for antibody therapeutics due to a growing healthcare infrastructure and increased incidences of chronic disease. Moreover, the Asia-Pacific region is witnessing growth in the antibody therapeutics market owing to the advances in personalized medicine and antibody development, supported by its strong research institutions and supportive government policies. Given their strong pharmaceutical industry, extensive research initiatives, and comprehensive intellectual property rights framework, European Union countries are pivotal in the antibody therapeutics landscape. In addition, countries in the Middle East and Africa are investing in state-of-the-art medical facilities and healthcare innovation.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibody Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AbCellera Biologics Inc., Adaptimmune Therapeutics PLC, ADC Therapeutics SA, Aenova Holding GmbH, Almac Group Limited, Amgen Inc., Antikor Biopharma, Argenx SE, Astellas Pharma Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biogen Inc., BioNTech SE, Bristol-Myers Squibb Company, Confo Therapeutics, DH Life Sciences, LLC, DotBio Pte. Ltd., Eli Lilly and Company, Emergent BioSolutions Inc., Evonik Industries AG, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc.,, Genmab A/S, GlaxoSmithKline PLC, Grifols, S.A., Incyte Corporation, iTeos Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Merus N.V., MoonLake Immunotherapeutics AG, MorphoSys AG, Novartis AG, Novo Nordisk A/S, Numab Therapeutics AG, Pfizer Inc., PharmAbcine Inc., Pyxis Oncology, Inc., Regeneron Pharmaceuticals, Inc., SAB Biotherapeutics, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., TRIO Pharmaceuticals Inc., UCB S.A., and Xencor, Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Format
- Antibody Fragment
- Bispecific Antibody
- Monoclonal Antibody
- Polyclonal Antibody
Route of Administration
- Intravenous
- Subcutaneous
Source
- Chimeric
- Human
- Humanized
Disease Areas
- Autoimmune & Inflammatory Diseases
- Hematology
- Immunology
- Neurology
- Oncology
- Osteology
End User
- Hospitals
- Long-term Care Facilities
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antibody Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Antibody Therapeutics Market?

4. What is the market share of the leading vendors in the Antibody Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Antibody Therapeutics Market?

Product Code: MRR-A42893A596EA

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Antibody Therapeutics Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising incidences of various cancers and infectious diseases
  - 5.1.1.2. Increasing number of drug discovery activities worldwide
  - 5.1.1.3. Government initiatives to promote access to antibody treatments and therapies
- 5.1.2. Restraints
  - 5.1.2.1. Incidences of product recalls of antibody therapeutics coupled with strict approval guidelines
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in the clinical development of antibody therapeutics
  - 5.1.3.2. Ongoing approvals for novel antibody therapies and treatments
- 5.1.4. Challenges
  - 5.1.4.1. Insufficient efficacy and adverse effects associated with various treatments
5.2. Market Segmentation Analysis
- 5.2.1. Format: Significant utilization of monoclonal antibodies due to numerous approvals by regulatory agencies for clinical use
- 5.2.2. Route of Administration: Growing usage of intravenous administration of antibody therapeutics
- 5.2.3. Source: Increasing use of human antibodies due to its biocompatible nature
- 5.2.4. Disease Areas: Proliferating use of antibody therapeutics for infectious diseases
- 5.2.5. End User: Evolving usage of antibody therapeutics in hospitals
5.3. Market Trend Analysis
- 5.3.1. Advanced R&D activities in antibody therapeutics backed by government funding and partnership activities by global established pharmaceutical companies in Americas
- 5.3.2. Growing burden of chronic and infectious diseases creating need for antibody therapeutics in the Asia-Pacific
- 5.3.3. Ongoing clinical trials coupled with expansion of biotech companies in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Antibody Therapeutics Market, by Format

6.1. Introduction
6.2. Antibody Fragment
6.3. Bispecific Antibody
6.4. Monoclonal Antibody
6.5. Polyclonal Antibody

7. Antibody Therapeutics Market, by Route of Administration

7.1. Introduction
7.2. Intravenous
7.3. Subcutaneous

8. Antibody Therapeutics Market, by Source

8.1. Introduction
8.2. Chimeric
8.3. Human
8.4. Humanized

9. Antibody Therapeutics Market, by Disease Areas

9.1. Introduction
9.2. Autoimmune & Inflammatory Diseases
9.3. Hematology
9.4. Immunology
9.5. Neurology
9.6. Oncology
9.7. Osteology

10. Antibody Therapeutics Market, by End User

10.1. Introduction
10.2. Hospitals
10.3. Long-term Care Facilities

11. Americas Antibody Therapeutics Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Antibody Therapeutics Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Antibody Therapeutics Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
- 14.3.1. Merger & Acquisition
  - 14.3.1.1. AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
  - 14.3.1.2. Pyxis Oncology to acquire Antibody Therapeutics Company Apexigen
  - 14.3.1.3. Merck to Develop mAb Through USD 10.8 Billion Acquisition
- 14.3.2. Agreement, Collaboration, & Partnership
  - 14.3.2.1. SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
  - 14.3.2.2. AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
  - 14.3.2.3. Salipro Partners with Icosagen to Develop Monoclonal Antibody Therapies
  - 14.3.2.4. AbCellera, Incyte Partner on Therapeutic Antibodies in Oncology
  - 14.3.2.5. Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
- 14.3.3. New Product Launch & Enhancement
  - 14.3.3.1. U.S. FDA Approves TALVEY, a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
- 14.3.4. Investment & Funding
  - 14.3.4.1. MBrace Therapeutics Raises USD 85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates
  - 14.3.4.2. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
  - 14.3.4.3. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
- 14.3.5. Award, Recognition, & Expansion
  - 14.3.5.1. Japan Grants Patent for Bioarctic's Parkinson's Disease Antibody

15. Competitive Portfolio

15.1. Key Company Profiles
- 15.1.1. AbbVie Inc.
- 15.1.2. AbCellera Biologics Inc.
- 15.1.3. Adaptimmune Therapeutics PLC
- 15.1.4. ADC Therapeutics SA
- 15.1.5. Aenova Holding GmbH
- 15.1.6. Almac Group Limited
- 15.1.7. Amgen Inc.
- 15.1.8. Antikor Biopharma
- 15.1.9. Argenx SE
- 15.1.10. Astellas Pharma Inc.
- 15.1.11. AstraZeneca PLC
- 15.1.12. Baxter International Inc.
- 15.1.13. Bayer AG
- 15.1.14. Becton, Dickinson and Company
- 15.1.15. Bio-Rad Laboratories, Inc.
- 15.1.16. Biogen Inc.
- 15.1.17. BioNTech SE
- 15.1.18. Bristol-Myers Squibb Company
- 15.1.19. Confo Therapeutics
- 15.1.20. DH Life Sciences, LLC
- 15.1.21. DotBio Pte. Ltd.
- 15.1.22. Eli Lilly and Company
- 15.1.23. Emergent BioSolutions Inc.
- 15.1.24. Evonik Industries AG
- 15.1.25. F. Hoffmann-La Roche Ltd.
- 15.1.26. GE HealthCare Technologies, Inc.,
- 15.1.27. Genmab A/S
- 15.1.28. GlaxoSmithKline PLC
- 15.1.29. Grifols, S.A.
- 15.1.30. Incyte Corporation
- 15.1.31. iTeos Therapeutics, Inc.
- 15.1.32. Johnson & Johnson Services, Inc.
- 15.1.33. Merck KGaA
- 15.1.34. Merus N.V.
- 15.1.35. MoonLake Immunotherapeutics AG
- 15.1.36. MorphoSys AG
- 15.1.37. Novartis AG
- 15.1.38. Novo Nordisk A/S
- 15.1.39. Numab Therapeutics AG
- 15.1.40. Pfizer Inc.
- 15.1.41. PharmAbcine Inc.
- 15.1.42. Pyxis Oncology, Inc.
- 15.1.43. Regeneron Pharmaceuticals, Inc.
- 15.1.44. SAB Biotherapeutics, Inc.
- 15.1.45. Sanofi S.A.
- 15.1.46. Takeda Pharmaceutical Company Limited
- 15.1.47. Thermo Fisher Scientific Inc.
- 15.1.48. TRIO Pharmaceuticals Inc.
- 15.1.49. UCB S.A.
- 15.1.50. Xencor, Inc.
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing